BioLife Solutions posted record revenue for the third quarter.
The fast-growing Bothell biotech reported revenue of $2.1 million in the third quarter, driven by sales of two high-demand products that store frozen tissue samples for cancer research.
"Demand for CryoStor and HypoThermosol continues to increase as more cell therapy companies and clinical centers embed our proprietary biopreservation media products into their manufacturing and logistics processes,” said President and CEO Mike Rice.…
BioLife Solutions posted record revenue for the third quarter.
The fast-growing Bothell biotech reported revenue of $2.1 million in the third quarter, driven by sales of two high-demand products that store frozen tissue samples for cancer research.
"Demand for CryoStor and HypoThermosol continues to increase as more cell therapy companies and clinical centers embed our proprietary biopreservation media products into their manufacturing and logistics processes,” said President and CEO Mike Rice.…